Process QCIs have several advantages, such as being closely related to outcomes, easily modifiable, and providing clear guidance for quality improvement efforts. 2 For example, the Quality Oncology Practice Initiative (QOPI) has provided medical oncology practices with the opportunity to participate in a practice-based quality of care self-assessment on a regular basis. 3, 4 Although QOPI sites have experienced performance improvements, 4 ,5 changing cancer care outside of QOPI may require other local, regional, or national efforts. 1 The American College of Surgeons (ACS) Commission on Cancer (COC), using hospital-based cancer registries to import high-quality data into the National Cancer Database (NCDB), provides feedback to participating sites on accountability and quality improvement measures.
The Florida Initiative for Quality Cancer Care (FIQCC), established in 2004, had the overall goal of evaluating and improving the quality of cancer care at a regional level in Florida. [6] [7] [8] [9] [10] The FIQCC is a consortium of 3 academic and 8 community practices that electively agreed to participate in a thorough practice-based selfassessment of quality indicators focusing on 3 common cancers (breast, colorectal, nonsmall cell lung [NSCLC] ). This project was conceived with the aim of identifying obstacles involved in the consistent delivery of quality cancer care, providing feedback to the sites, and enabling quality of cancer care improvements at these participating sites. Here, we examined QCIs for breast cancer assessed during 2 time periods (2006 and 2009), with disclosure of the results to the consortium in 2008 and 2012. Our objectives were to examine the overall difference in adherence between the 2 assessments; to determine if change over time was independent of other factors that could have changed over time; and to determine if variability among the practice sites still remained.
METHODS

Selection of practices
When formed in 2004, the FIQCC consisted of 11 medical oncology practices in Florida (Appendix Fig. 1 , online only). 10 Each practice met the following criteria for initial participation: medical oncology services provided by more than 1 oncologist; availability of a medical record abstractor; and estimate of 40 or more cases each of colorectal, breast, and NSCLC for calendar year 2006. Ten practices still met eligibility criteria to participate in the 2009 abstraction. The project received approval from Institutional Review Boards at each institution. Based on exempt status, informed consent from patients was not required. To maintain patient privacy, records were coded with a unique project identifier before transmission to the central data management site.
Selection of indicators
In 2005, representatives from the participating FIQCC sites identified quality measures consistent with evidence-, consensus-, and safety-based guidelines that could be abstracted from medical records of breast, colorectal, and NSCLC patients. The indicators selected were from wellaccepted standard indicatorsdQOPI, National Comprehensive Cancer Network (NCCN), COC, and by panel consensus of the principal investigators from each FIQCC site. [11] [12] [13] [14] [15] [16] Consensus among the investigators at Moffitt Cancer Center and the site principal investigators was required for each indicator. The resulting indicators were organized by diagnosis (breast, colorectal, and NSCLC) and by domains of care (eg, symptom management). In this article, we focused only on results of 30 main quality indicators and their subcategories of breast cancer patients. 6 Chart reviews/abstraction/quality control Medical chart reviews were conducted on randomly sampled patients (>18 years of age) diagnosed with invasive breast cancer in 2006 and on randomly selected corresponding newly diagnosed patients in 2009. Chart review and quality control procedures were conducted throughout the study as reported previously, 7, 10, 17 including training of chart reviewers using the comprehensive abstraction manual and quality control of retrieved data via 2 audits, both performed by the chief abstractor. sites. Potential explanations for variance among the sites, such as age distribution of a site's patient population, community vs academic center, and large vs small volume practice, were analyzed and discussed. 6, 18, 19 At the conference, a strategic plan was drafted in which site representatives would share analysis results with their respective practices and multidisciplinary cancer committees or tumor boards, thereby disseminating all QCIs across disciplines. Each practice was tasked with developing and implementing a site-specific quality improvement plan for any performance indicator <85%. The same chart abstraction process would be repeated with 2009 cases to assess changes in all indicators.
Formalized and uniform quality improvement efforts were not conducted for several reasons: to determine whether sharing data and site-specific quality improvement efforts resulted in changes in adherence before launching large-scale quality improvement efforts; a standardized quality improvement "algorithm" may not be feasible across all sites given the variability in practice/ institutional characteristics; and autonomy to design and implement their own quality improvement plan, as opposed to a mandated algorithm, fostered buy-in from the individualized health care providers at each respective site.
Statistical analysis
To compare case characteristics between 2006 and 2009, we used Pearson chi-square exact test, using Monte Carlo estimation. Each indicator variable was summarized using descriptive statistics and graphic illustrations. The adherence proportion (% of yes for each indicator) with its 95% confidence interval was calculated based on the exact binomial distribution. Comparisons of QCIs between 2006 and 2009 data and across practice sites were also made by the Pearson chi-square exact test. Multivariable logistic regression models were used to evaluate whether the effects of time (2006 vs 2009) on adherence to QCIs were independent of practice site. We tested the effects of practice site variation across time in a logistic regression model. Firth's penalized maximum likelihood estimation was used to fit the logistic regression models for small sample sizes. 20, 21 A p value of 0.05 (2-sided test) was declared significant. All analyses were conducted using SAS 9.3 (SAS Institute Inc).
RESULTS
Case characteristics
Our analyses included 1,238 invasive breast cancer cases from 10 FIQCC sites (602 patients from 2006 and 636 from 2009) ( Table 1) . Across the consortium, a few patients had their surgical procedures performed at an academic center but returned to their respective communities for medical/radiation oncology care. The median age of the patients was 60 years (range 22 to 95 Table 2 . Pathology QCIs were applied only to patients who were staged nonmetastatic, had surgery, and had a pathology report in their medical records. We Other indicators without significant changes included discussion or recommendation of adjuvant trastuzumab for Her2Neu-positive disease (81.3% vs 82.4%; p ¼ 1.000), discussion or recommendation for administration of an aromatase inhibitor, tamoxifen, or fulvestrant in metastatic estrogen receptor/progesterone receptor-positive breast cancer (p ¼ 1.000), and rationale for not administering treatment (96.0% vs 98%; p ¼ 1.000) ( Table 3) .
Although a high adherence rate was evident initially, documentation that a discussion/recommendation for adjuvant therapy with an aromatase inhibitor and/or tamoxifen improved significantly over time from 97.9% Positive changes in adherence were also seen for documentation of the planned dose of chemotherapy falling within the published regimen range (74% vs 84%; p ¼ 0.020) and selection of chemotherapy for patients with metastatic disease from an approved list (89% vs 100%; p ¼ 0.017).
Variability in adherence across practice sites To examine if adherence changes over time were consistent across the practice sites, adherence rate was visualized graphically (Fig. 1) , and an interaction term of practice site and time was tested in multivariable logistic regression models. There was significant variability in the magnitude and direction of the change in adherence over time for several QCIs, which was not evident when examining aggregate changes over time across all sites. As demonstrated in Figure 1A , change in documentation of the patient's menopausal status varied by oncology practice, ranging from a decrease of 30% to an increase in 60% of cases. This variability in change in adherence over time was statistically significant in logistic regression modeling of the interaction between time and practice site (p < 0.0001, data not shown). However, we found no change in performance on the quality indicator for all sites combined. This was similarly seen with documentation of family history (site-by-time interaction, p ¼ 0.008, data not shown) and mammography within 14 months of definitive (site-by-time interaction, p ¼ 0.009).
In contrast, changes over time were consistent across practice sites for several QCIs, including documenting that the surgical specimen was inked and oriented (siteby-time interaction, p ¼ 0. Lastly, as evident in Figure 1D , some QCIs (eg, overall performance of documenting informed consent) improved over time (p ¼ 0.047), and there was significant variability among practice sites in the magnitude and direction of the change (p ¼ 0.021). Some practice sites increased adherence (eg, 1 site had a positive change of 29%); others decreased (eg, negative 14% change for 1 site).
DISCUSSION
The FIQCC consortium conducted repetitive quality of cancer care assessments for 10 Florida medical oncology practices. The FIQCC framework afforded us the opportunity to compare adherence to QCIs for each site for 2006 vs 2009. Notably, because FIQCC assessment results were shared with respective Institutional Quality Review committees and/or multidisciplinary tumor board meetings, improvement efforts at sites were not only "practice-driven" but "physician-driven." Each site selected which quality indicators they would focus their efforts on, explaining why some metrics may have been high overall for the FIQCC consortium but low at a particular practice site. Variability of magnitude and direction of change between sites were therefore analyzed in addition to aggregate data to uncover improvements seen at the practice level.
Significant improvements were seen among a few medical/radiation oncology indicators that were low at baseline (2006) but failed to achieve >85% performance in 2009 (eg, documentation of informed consent). A variety of approaches to improve informed consent documentation were undertaken, including requiring a standardized, signed informed consent document before administration One site needed to incorporate the outside hormone receptor report. Auditing and monitoring the completeness of pathology reports has been shown to improve report quality. 13, 14, 22, 23 Therefore, the FIQCC may have positively affected the quality between assessments, as evidenced by the presence of the AJCC staging system on the pathology report. However, the impact was different among the sites, as shown by a statistically significant interaction between practice site and the magnitude of change over time.
Similar to the medical/radiation oncology indicators, no surgical and pathology indicators significantly regressed. Performance of SLNB improved significantly over time. Although the variability of change across practice sites was statistically significant, for most sites this change was an increase in use resulting from feedback by our medical oncology practices to local surgeons and changes in the College of American Pathologists reporting template requiring AJCC inclusion of nodal status by category. Performance of a complete CALND for SLNB-positive disease, however, did not improve significantly. A decline in this indicator was already evident nationally before the American College of Surgeons Oncology Group Z0011 data findings were published and therefore may be reflected in our findings. 16 Even with these successes, our approach has limitations. Some sites reported barriers in implementing improvement efforts for some QCIs, as a result of conversion to an electronic medical record or collecting documents from non-FIQCC sites. This explained those indicators that remained low over time, including documentation of menopausal status, family history, planned chemotherapy regimen, and performance of a mammogram within 14 months of definitive surgery.
Improving the quality of care within any medical specialty requires high-quality data, efficient mechanisms to provide feedback of the results to hospitals/practices, systems adaptable to act on the needed changes based on the data, and acknowledgement/acceptance from the providers. 15 Improvements in oncology practice performance via QOPI have been consistently reported nationally 4 ; however, QOPI provides only site-specific feedback. In contrast, the COC's NCDB provides feedback to each participating site in comparison to other centers within their region, state, or nationally. 11, 12 The COC centers usually have more cancer-related services available to patients. This results in certain limitations extrapolating data analysis results to the public at large. The FIQCC overcomes these limitations based on its selected practice sites (academic institutions, community-based medical oncology practices). So, the FIQCC is a better reflection of the standard of practice for quality of cancer care within the state of Florida. The FIQCC, with its structure of evaluating performance measures and site-directed intervention, allows for improvement and maintenance of our quality indicators over time at each site. Being able to discuss quality improvement strategies among the sites in an open forum has allowed each site to take advantage of lessons learned.
Tracking adherence to quality indicators, interventions used, and reassessments of performance pose challenges. The success of our project was dependent on site and site representative engagement. With the changing dynamics of health care, adaptability will be required to successfully deliver and document quality cancer care in the future. Areas of deficiency will need to be identified, while barriers are deconstructed. Organizational commitment, leadership support, resources, and communication are 4 factors essential to successful improvements in treatment measurements and reporting. 24 Institutional commitment requires a financial investment for resources, training, and sustainability as well as physician commitment. Leadership support entails the appreciation of the nonrevenue-earning time submitted by specialists who supervise the quality improvement process. Finally, communication among all components of the hospital/ practice is needed so that cyclical analysis of data, feedback of information, development and implementation of quality improvement plans, and finally, reassessment of success or failure can be cost-and time-efficient, streamlined, and nonredundant.
CONCLUSIONS
In summary, improvements in QCI adherence over a 3-year period highlighted the dedication of each practice site in conducting self-directed improvement efforts. Improvements in QCI were seen in each discipline, demonstrating the true multidisciplinary coordination of care that occurs in treating cancer patients. The FIQCC serves as a model by which identification, re-education, and intervention can positively affect quality cancer care done on a local or regional level. A focus on quality of care will lead to improvements and ultimately, excellence in delivery of cancer care.
